Inicio>>Signaling Pathways>> Microbiology & Virology>> Parasite>>Diclazuril

Diclazuril (Synonyms: R-64433)

Catalog No.GC14878

Diclazuril (R-64433), un derivado del bencenoacetonitrilo, es un agente anticoccidial potente y activo por vÍa oral.

Products are for research use only. Not for human use. We do not sell to patients.

Diclazuril Chemical Structure

Cas No.: 101831-37-2

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
37,00 $
Disponible
50mg
33,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Diclazuril (R-64433) is an anti-coccidial drug.

Diclazuril (R-64433) is a coccidiostat, the lambs treated with diclazuril showed an intense, persistent oocyst excretion, with average levels of 97.54 opg, considerably higher than those recorded in the animals treated with toltrazuril (p < 0.05)[1]. Diclazuril (R-64433) is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril (R-64433) was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima[2].

References:
[1]. Diaferia, M., et al., Efficacy of toltrazuril 5 % suspension (Baycox(R), Bayer) and diclazuril (Vecoxan(R), Janssen-Cilag) in the control of Eimeria spp. in lambs. Parasitol Res, 2013. 112 Suppl 1: p. 163-8.
[2]. http://www.huvepharma.com/products/view/190

Reseñas

Review for Diclazuril

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Diclazuril

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.